Table 2.
Clinical and molecular characteristics of radiomics-defined subtypes.
| Cluster 1 | Cluster 2 | Cluster 3 | p-value | |
|---|---|---|---|---|
| Training cohort | ||||
| No. of patients (No. of patients with WTS data) |
57 (34) | 67 (39) | 23 (13) | |
| Age (years) | 57.6 | 59.8 | 52.3 | 0.277 * |
| Sex (male (%)) | 56.1 (32/57) | 53.7 (36/67) | 52.2% (12/23) | 0.926 ** |
| pMGMT methylation (methylation (%)) |
42.1 (24/57) |
53.0 (35/66) |
59.1 (13/22) |
0.314 ** |
| IDH1 mutation (mutant (%)) |
1.9 (2/55) |
3.2 (2/64) |
10.5 (2/21) |
0.223 ** |
| Operation extent (GTR (%)) |
45.6 (26/57) | 59.7 (40/67) | 60.9 (14/23) | 0.234 ** |
| Validation cohort | ||||
| No. of patients (No. of patients with WTS data) |
17 (0) | 39 (0) | 0 | |
| Age (years) | 58.1 | 56.4 | NA | 0.648 *** |
| Sex (male (%)) | 70.6 (12/17) | 61.5 (24/39) | NA | 0.561 ** |
| pMGMT methylation (methylation (%)) |
NA | NA | NA | NA |
| IDH1 mutation (mutant (%)) |
0 (0/11) | 10 (3/30) | NA | 0.551 ** |
| Operation extent (GTR (%)) |
42.9 (3/7) | 47.8 (11/23) | NA | 1 ** |
* ANOVA; ** Fisher’s exact test; *** Kruskal–Wallis test; Abbreviations: No, number; NA, not applicable; WTS, whole transcriptome sequencing; pMGMT, MGMT promoter; GTR, gross total resection.